AcelRx: Non-Opioid Pain Agent Launched in Europe

 Physicians across Europe will now have access to DZUVEO®, a novel sublingual approach to acute pain management in medically supervised settings

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that its commercial partner, Laboratorie Aguettant ("Aguettant"), has launched DZUVEO® (sufentanil sublingual tablet, 30 mcg), which is branded as DSUVIA® in the U.S., across Europe.

Aguettant entered into a commercial collaboration with AcelRx in 2021 and has formally launched across key European countries, except Spain, Portugal and Italy, for which commercialization is expected to begin in the first half of 2023.  Physicians across Europe will now have access to DZUVEO, a sublingual alternative to standard intravenous (IV) opioid analgesics which have undesirable pharmacokinetic and pharmacodynamic performance profiles characterized by high peak plasma concentrations and the requirement for frequent redosing.  DSUVIA/DZUVEO was designed to provide rapid analgesia via a non-invasive route and to eliminate high peak plasma levels, provide longer duration of action, and avoid dosing errors associated with IV administration.  In addition, a number of recently published U.S. studies demonstrate that a sufentanil sublingual tablet, 30 mcg administered in various medically supervised settings can lower overall perioperative opioid use, as well as shorten recovery time, compared to IV opioids.

https://finance.yahoo.com/news/acelrx-pharmaceuticals-announces-european-launch-123000925.html